GlassScriptPhysician profile
Jennifer Willey
NPI 1104217595
$2,762.69
in general payments reported to CMS, 2019-2025
32 companies · $70.84 in 2025
The $70.84 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $670 · 2023: $775 · 2024: $507 · 2025: $70.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.39 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $387.82 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $343.25 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.62 | 2021-2023 | Jardiance |
| Abbvie INC. | $180.28 | 2021-2023 | |
| Astellas Pharma US INC | $179.33 | 2023-2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $174.08 | 2021-2025 | Breztri, Airsupra |
| Daiichi Sankyo INC. | $153.41 | 2021-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $150.69 | 2021-2024 | Trintellix |
| Amgen INC. | $117.26 | 2021-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $112.25 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $97.14 | 2022-2024 | |
| Exact Sciences Corporation | $96.04 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $81.49 | 2021-2024 | |
| Lundbeck LLC | $74.23 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.50 | 2023 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $31.69 | 2022 | |
| Corcept Therapeutics | $28.62 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $28.16 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $24.70 | 2023 | Quviviq |
| Abbott Laboratories | $24.54 | 2023 | Proclaim |
| Amarin Pharma, INC. | $22.35 | 2021 | |
| Dexcom, INC. | $21.77 | 2022 | |
| Sumitomo Pharma America, INC. | $21.37 | 2024 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $21.32 | 2023 | Strensiq |
| Vbi Vaccine (Delaware) INC. | $19.68 | 2023 | Prehevbrio |
| Merck Sharp & Dohme LLC | $19.10 | 2022 | |
| Esperion Therapeutics, INC. | $18.84 | 2022 | |
| Linus Health, INC. | $18.58 | 2023 | |
| Horizon Therapeutics Plc | $17.15 | 2021 | |
| Bausch Health US, LLC | $17.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.51 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Willey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.